Interim advance at Abbey Protection 02/09/2010
Legal fees and related insurance and services specialist Abbey Protection has increased first-half pre-tax profits 9.3 per cent to £4.7 million.
US group Metagenics is launching biotech counter ReGen Therapeutics’ Colostrinin neurodegenerative treatment in America.
Chaired by the persistently cheerful Percy Lomax, ReGen, whose shares have been AIM dogs for years, says it expects to make around $4.75 (£2.37) from every Colostrinin unit sold under the licensing deal by California-based Metagenics, which is planning to float shortly in the USA. Lomax says Colostrinin, a non-prescription refinement of an already available but relatively ineffective product, has shown efficacy in treating Alzheimer's disease and could make £5 million a year from this deal from 2009.
He argues Colostrinin could be useful against other ailments such as Parkinson's disease, multiple sclerosis and even cancer. Meanwhile, ReGen has other irons in the fire, notably Zolpidem.
This is an off-patent insomnia drug, which, according to 'open' clinical observations, has on occasion 'normalised' brain dormancy after strokes, traumatic brain injuries, vascular dementia and Bell's palsy. The company says there could be significant developments late next year or early in 2009.
Of all goes well, Lomax suggests ReGen, which lost £1.5 million in the six months to June, could be in a position to start making sustainable profits by the end of 2008. If achieved, that would be welcome news indeed for investors who have seen the shares crumble from 2000's float price of 28p to a barely perceptible 0.75p today.
Growth Company Investor subscribers have full access to all our AIM and small-cap share recommendations. To subscribe today with a half-price offer, and gain immediate access to all the recommendations, click here.
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.
Advertisement
Legal fees and related insurance and services specialist Abbey Protection has increased first-half pre-tax profits 9.3 per cent to £4.7 million.
Workwear rental and facilities management concern Johnson Service Group is feeling acquisitive after losing a first-half £2.2 million pre-tax.
'Green' food safety and life sciences group PuriCore targets monthly profits by late 2011 after trimming first-half losses to $5.1 million (£3.3 million).